Nektelise®
INN: tenecteplase
Description
Indications for use
A tissue-type plasminogen activator obtained using recombinant DNA technology with CHO cell line, containing modified amino acid residues in three regions of the natural human protein that determine tenecteplase's high specificity to fibrin and resistance to plasminogen activator inhibitor-1. Due to the modifications made, the drug is administered as a single bolus.
The first biosimilar of tenecteplase registered in Russia. All stages of production of Nektelize® are carried out on the territory of the Russian Federation.
LP-(009170)-(RG-RU)
- Thrombolytic therapy of acute myocardial infarction in adult patients aged 18 years and older.
- Thrombolytic therapy of acute ischemic stroke in adults within 4.5 hours from the onset of symptoms and after exclusion of intracranial hemorrhage.